下载掌阅APP，畅读海量书库
立即打开
［1］TURPIE A G，ERIKSSON B I，LASSEN M R，et al. Fondaparinux，the first selective factor Ⅹ a inhibitor［J］. Curr Opin Hematol，2003，10（5）: 327-332.
［2］杨雪松，喻卓.磺达肝癸钠在急性冠状动脉综合征治疗中的研究现状［J］.中国医药指南，2011，9（23）:227-229.
［3］朱振安.预防骨科大手术后静脉血栓的新型抗凝药物——磺达肝癸钠［J］.中华关节外科杂志（电子版），2009，3（1）:71-72.
［4］BAUER K A. Fondaparinux sodium: a selective inhibitor of factorⅩa［J］. Am J Health Syst Pharm，2001，58 Suppl 2: S14-S17.
［5］TURPIE A G，GALLUS A S，HOEK J A，et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement［J］. N Engl J Med，2001，344（9）:619-625.
［6］BONEU B，NECCIARI J，CARIOU R，et al. Pharmacokinetics and tolerance of the natural pentasaccharide（SR90107/Org31540）with high affinity to antithrombin Ⅲ in man［J］.Thromb Haemost，1995，74（6）: 1468-1473.
［7］NAGLER M，HASLAUER M，WUILLEMIN W A. Fondaparinux -data on efficacy and safety in special situations［J］. Thromb Res，2012，129（4）: 407-417.
［8］COPE J，BUSHWITZ J，AN G，et al. Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy［J］. Ann Pharmacother，2015，49（3）: 270-277.
［9］KENNETH A B.磺达肝癸的用法用量及不良反应. ［2023-05-06］.http://121.4.192.30:8091/contents/zh-Hans/fondaparinux-dosingand-adverse-effects?search.
［10］SHEN X F，WILE R，YOUNG G. FondaKIDS Ⅲ: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children［J］. Pediatr Blood Cancer，2020，67（8）: e28295.
［11］GARCIA D A ，BAGLIN T P，WEITZ J I，et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis，9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest， 2012，141（2 Suppl）: e24S-e43S.
［12］CHENG J W. Fondaparinux: a new antithrombotic agent［J］.Clin Ther，2002，24（11）: 1757-1769,1719.
［13］WIENBERGEN H，ZEYMER U. Management of acute coronary syndromes with fondaparinux［J］. Vasc Health Risk Manag，2007，3（3）: 321-329.